EntryPoint Capital LLC Has $281,000 Position in Exelixis, Inc. (NASDAQ:EXEL)

EntryPoint Capital LLC lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 54.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,433 shares of the biotechnology company's stock after selling 10,230 shares during the quarter. EntryPoint Capital LLC's holdings in Exelixis were worth $281,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXEL. Vanguard Group Inc. boosted its stake in shares of Exelixis by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after acquiring an additional 121,750 shares during the period. FMR LLC boosted its position in Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock worth $63,891,000 after purchasing an additional 140,568 shares during the period. Los Angeles Capital Management LLC boosted its position in Exelixis by 20.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company's stock worth $71,828,000 after purchasing an additional 366,141 shares during the period. Two Sigma Advisers LP increased its holdings in shares of Exelixis by 6.1% in the third quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company's stock valued at $44,182,000 after purchasing an additional 98,000 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after purchasing an additional 704,786 shares during the period. Institutional investors own 85.27% of the company's stock.

Remove Ads

Insider Activity at Exelixis

In related news, Director Bob Oliver sold 18,647 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total transaction of $694,600.75. Following the sale, the director now owns 33,514 shares of the company's stock, valued at $1,248,396.50. This trade represents a 35.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the transaction, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. The trade was a 3.62 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is owned by insiders.

Exelixis Trading Down 1.4 %

NASDAQ EXEL traded down $0.53 on Tuesday, hitting $36.39. 2,799,603 shares of the company's stock were exchanged, compared to its average volume of 2,145,989. The stock has a 50-day moving average of $35.72 and a 200-day moving average of $33.46. The stock has a market cap of $10.18 billion, a price-to-earnings ratio of 20.56, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Wells Fargo & Company lowered shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 price target on the stock. in a research note on Monday, February 24th. UBS Group boosted their price objective on Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Exelixis in a research note on Thursday, March 27th. Citigroup lifted their price target on Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Finally, Bank of America lowered Exelixis from a "buy" rating to a "neutral" rating and upped their price objective for the company from $35.00 to $39.00 in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.